Reduction of advanced glycation endproducts from bodily fluids

Abstract

The invention concerns removing advanced glycation end products from a bodily fluid by contacting the bodily fluid with a sorbent.

What is claimed: 
     
         1 . A method of removing advanced glycation end products from a bodily fluid comprising contacting said bodily fluid with a sorbent. 
     
     
         2 . The method of  claim 1 , wherein the sorbent comprises a plurality of pores ranging from 50 Å to 40,000 Å with a pore volume of 0.5 cc/g to 5.0 cc/g and a size of 0.05 mm to 2 cm. 
     
     
         3 . The method of  claim 1  or  claim 2 , wherein the sorbent is biocompatible. 
     
     
         4 . The method of any one of  claims 1 - 3 , wherein the bodily fluid comprises saliva, nasopharyngeal fluid, blood, plasma, serum, saliva, gastrointestinal fluid, bile, cerebrospinal fluid, pericardial, vaginal fluid, seminal fluid, prostatic fluid, peritoneal fluid, pleural fluid, urine, synovial fluid, interstitial fluid, intracellular fluid, extracellular fluid, lymph, mucus, or vitreous humor. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein the sorbent has a pore structure such that the total pore volume of pore size in the range of 50 Å to 40,000 Å is greater than 0.5 cc/g to 5.0 cc/g dry sorbent; wherein the ratio of pore volume between 50 Å to 40,000 Å (pore diameter) to pore volume between 1,000 Å to 10,000 Å (pore diameter) of the sorbent is smaller than 2:1. 
     
     
         6 . The method of any one of  claims 1 - 5 , wherein the sorbent comprises at least one crosslinking agent and at least one monomer. 
     
     
         7 . The method of any one of  claims 1 - 5 , wherein the sorbent comprises at least one crosslinking agent, at least one monomer, at least one dispersing agent and at least one porogen. 
     
     
         8 . The method of  claim 7 , wherein the dispersing agent is one or more of hydroxyethyl cellulose, hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), poly(hydroxyethyl acrylate), poly(hydroxypropyl methacrylate), poly(hydroxypropyl acrylate), poly(dimethylaminoethyl methacrylate), poly(dimethylaminoethyl acrylate), poly(diethylaminoethyl methacrylate), poly(diethylaminoethyl acrylate), poly(vinyl alcohol), poly(N-vinylpyrrolidinone), salts of poly(methacrylic acid), or salts of poly(acrylic acid). 
     
     
         9 . The method of  claim 6  or  7 , wherein the crosslinking agent is one or more of divinylbenzene, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythrital dimethacrylates, pentaerythrital trimethacrylates, pentaerythrital, tetramethacrylates, pentaerythritol diacrylates, pentaerythritol triiacrylates, pentaerythritol tetraacrylates, dipentaerythritol dimethacrylates, dipentaerythritol trimethacrylates, dipentaerythritol tetramethacrylates, dipentaerythritol diacrylates, dipentaerythritol triacrylates, dipentaerythritol tetraacrylates, or divinylformamide. 
     
     
         10 . The method of  claim 6  or  7 , wherein the monomer is one or more of divinylbenzene and ethylvinylbezene, styrene, ethylstyrene, acrylonitrile, butyl methacrylate, octyl methacrylate, butyl acrylate, octyl acrylate, cetyl methacrylate, cetyl acrylate, ethyl methacrylate, ethyl acrylate, vinyltoluene, vinylnaphthalene, vinylbenzyl alcohol, vinylformamide, methyl methacrylate, methyl acrylate, trivinylbenzene, divinylnaphthalene, trivinylcyclohexane, divinylsulfone, trimethylolpropane trimethacrylate, trimethylolpropane dimethacrylate, trimethylolpropane triacrylate, trimethylolpropane diacrylate, pentaerythritol dimethacrylate, pentaerythritol trimethacrylate, pentaerythritol tetramethacrylate, pentaerythritol diacrylate, pentaerythritol triiacrylate, pentaerythritol tetraacrylate, dipentaerythritol dimethacrylate, dipentaerythritol trimethacrylate, dipentaerythritol tetramethacrylate, dipentaerythritol diacrylate, dipentaerythritol triacrylate, dipentaerythritol tetraacrylate, divinylformamide and mixtures thereof. 
     
     
         11 . The method of  claim 7 , wherein the porogen is one or more of benzyl alcohol, cyclohexane, cyclohexanol, cyclohexanol/toluene mixtures, cyclohexanone, decane, decane/toluene mixtures, di-2-ethylhexylphosphoric acid, di-2-ethylhexyl phthalate, 2-ethyl-1-hexanoic acid, 2-ethyl-1-hexanol, 2-ethyl-1-hexanol/n-heptane mixtures, 2-ethyl-1-hexanol/toluene mixtures, isoamyl alcohol, n-heptane, n-heptane/ethylacetate, n-heptane/isoamyl acetate, n-heptane/tetraline mixtures, n-heptane/toluene mixtures, n-hexane/toluene mixtures, pentanol, poly(styrene-co-methyl methacrylate)/dibutyl phthalate, polystyrene/2-ethyl-1-hexanol mixtures, polystyrene/dibutyl phthalate, polystyrene/n-hexane mixtures, polystyrene/toluene mixtures, toluene, tri-n-butylphosphate, 1,2,3-trichloropropane/2-ethyl-1-hexanol mixtures, 2,2,4-trimethyl pentane (isooctane), trimethyl pentane/toluene mixtures, poly(propylene glycol)/toluene mixtures poly(propylene glycol)/cyclohexanol mixtures, and poly(propylene glycol)/2-ethyl-1-hexanol mixtures. 
     
     
         12 . The method of any one of  claims 1 - 11  wherein the contacting occurs ex vivo. 
     
     
         13 . The method of any one of  claims 1 - 11  wherein the contacting occurs in vivo. 
     
     
         14 . The treatment of a degenerative disease comprising the method of any one of  claims 1 - 13 . 
     
     
         15 . The treatment of  claim 14  wherein the degenerative disease is Alzheimer's disease. 
     
     
         16 . The treatment of  claim 14 , wherein the degenerative disease is a macular degeneration. 
     
     
         17 . The treatment of  claim 14 , wherein the degenerative disease is osteoarthritis. 
     
     
         18 . The treatment of  claim 14 , wherein the degenerative disease is atherosclerosis. 
     
     
         19 . The treatment of  claim 14 , wherein the degenerative disease is heart disease or kidney failure.